Barclays’s Verona Pharma VRNA Stock Holding History

Barclays’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,393,716	Closed	-$149M	–	5735
2025 Q3	$149M	Buy	1,393,716 +1,283,105	+1,160%	+$134M	0.03%	379
2025 Q2	$10.5M	Buy	110,611 +1,110	+1%	+$82.2K	﹤0.01%	1551
2025 Q1	$6.95M	Buy	109,501 +104,188	+1,961%	+$6.23M	﹤0.01%	1661
2024 Q4	$247K	Buy	5,313 +4,954	+1,380%	+$186K	﹤0.01%	4209
2024 Q3	$10.3K	Buy	+359	New	+$8.84K	﹤0.01%	4971
2021 Q4	–	Sell	-12	Closed	–	–	4774
2021 Q3	$0	Buy	12 +2	+20%	+$12	﹤0.01%	5041
2021 Q2	$0	Sell	10 -100	-91%	-$693	﹤0.01%	5102
2021 Q1	$1K	Buy	+110	New	+$913	﹤0.01%	4612

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Barclays's VRNA Position: Q4 2025 in Review

Barclays sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,393,716 shares — an estimated $149M sold.

Barclays first reported a position in VRNA in Q1 2021 and held it in 8 quarters. The position peaked at $149M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Barclays reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Barclays sold 1,393,716 Verona Pharma shares in Q4 2025, an estimated $149M.
Barclays first reported a position in Verona Pharma in Q1 2021 and held it in 8 quarters.
Barclays's Verona Pharma position peaked at $149M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.